€ 72 million for ViCentra accelerates global scaling of insulin pumps

International growth 

ViCentra is focusing on the international diabetes market with its Kaleido 2 insulin patch pump. The Dutch medtech company develops the smallest, lightest, and only consumer-designed insulin pump in its class. With the new capital, ViCentra can significantly scale up the production of Kaleido 2, launch in Europe, and prepare for the step into the American market.  

Major investment round confirms confidence 

With €72 million, this financial round is among the largest medtech investments in the Netherlands this year. Innovation Industries led the funding round for ViCentra. Besides Invest-NL, existing shareholder Partners in Equity and EQT Life Sciences and Health Innovation also invested in this round. The broad participation demonstrates that current and new investors have confidence in the future and success of ViCentra.  

Impact on quality of life 

Worldwide, the number of people with diabetes is increasing, along with the need for user-friendly and reliable treatment options. “ViCentra combines proven technology with a design that puts the user at the centre. This makes their solution not only medically effective but also comfortable in everyday life. With this investment, ViCentra can help significantly more users, which has a tremendous impact on the quality of life of diabetes patients,” says Ineke Cazander, investment principal at Invest-NL.  

The investment in ViCentra aligns with our mission to accelerate societal transitions. Within the Life Sciences & Health sector, there is a strong demand for risk capital. By investing, we support groundbreaking healthcare innovations and build a healthy future.